BCR-ABL-IN-7

BCR-ABL-IN-7 (compound 4) is a WT and T315I mutant ABL kinases inhibitor. BCR-ABL-IN-7 effectively inhibits activities of WT and T315I mutant ABL kinases. BCR-ABL-IN-7 can be used for the research of chronic myeloid leukemia (CML) research[1].

Product Specifications

CAS Number

[688050-42-2]

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

Bcr-Abl

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/bcr-abl-in-7.html

Purity

99.66

Solubility

DMSO : 2 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(C1=C(NC(C2=NOC(C3=CC=C(F)C=C3)=C2)=O)SC4=C1CCCC4)N

Molecular Formula

C19H16FN3O3S

Molecular Weight

385.41

Precautions

H302, H315, H319

References & Citations

[1]Cao R, et al. Discovery of 2-Acylaminothiophene-3-Carboxamides as Multitarget Inhibitors for BCR-ABL Kinase and Microtubules. J Chem Inf Model. 2015 Nov 23;55 (11) :2435-42.